HCS Pharma start the year 2024 with a brand new strength! The new laboratories are welcome to continue to satisfy medical researchers and receive more and more demand from all around the world for our physiological and biological matrix BIOMIMESYS®. May our new premises be the theatre of more collaboration Read more…
HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…
This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…
In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On this occasion, the 3 companies have highlighted their work on hiPSCs (human induced Pluripotent Stem Read more…
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, and personalized medicine. Recent advancements in organoid research have focused on improving their complexity and Read more…
After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular carcinoma cell line) in Biochip, the project continue with Rania Chibani, who has joined us for a Read more…
After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
Our project leader Méryl and our CBO Mathieu are currently attending CellME (Cell Manufacturing & Engineering) Forum taking place these days in Berlin, Germany. Méryl had the chance to present his work and the advantages of BIOMIMESYS® for organoid culture earlier today: Please feel free to discuss with them on Read more…
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…
Dans le cadre de notre développement, nous recrutons un(e) Technicien(ne) en recherche et développement axée sur des modèles hépatiques in vitro. Vous serez en charge de : Gestion du laboratoire (commandes, entretien des machines, règles HSE, gestion des stocks) Maintien des cultures cellulaires en routine (lignées, cellules primaires, cellules souches, etc…) Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this webinar we will focus on BIOMIMESYS® Liver and will discuss about its different applications. Read more…
The current hiPSC-derived models are adapted to reproduce diseases of genetic origin in two dimensions and have allowed in recent years to model diseases by using hepatocyte-like-cells (HCL) such as: Alpha1-antitrypsin (A1AT) deficiency (Tafaleng et al., 2015) Familial transthyretin-related amyloidosis (ATTR) (Isono et al., 2014) Glycogen storage deficiency (Satoh et Read more…
When Tuesday, May 31, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 2, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, using zoom.us and live on Youtube What 3D cell culture systems have recently emerged as Read more…
Scanning Electron Microscopy (EM) has been an indispensable tool for Biological sciences. A great challenge was propelled by the need to find methods to better preserve and analyze structures at a state closest to the native state. With BIOMIMESYS® hydroscaffold technology, we have developed a new method to use SEM Read more…
The current hiPSC-derived models are adapted to reproduce diseases of genetic origin. However, the current two-dimensional HLC (hepatocyte like-cells) model has an immature liver phenotype that is more is closer to a perinatal liver. Furthermore, it does not take into account the complexity of the tissues and the extracellular environment Read more…
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of Read more…
The extracellular matrix (ECM) is a non-cellular component of tissues and organs. It is mainly composed of structural elements (proteoglycans collagens, elastin) and cell adhesion proteins such as fibronectin and laminins. The ECM forms a complex structure with physical properties (elasticity, tensile and compression strength), which provides physical support for Read more…
Launched in 2016, the adventure is coming to an end after 5 years of work carried out within the RHU CHOPIN (CHOlesterol Personalized INnovation), and with a strong collaboration between HCS Pharma and l’Institut du thorax. This collaborative project of national scope was led by Professor Bertrand Cariou, director of Read more…
A relevant liver in vitro model should display CYP inducibility that mimics in vivo metabolic responsiveness to known modulators. This response of CYPs to induction is a critical parameter for predicting adverse drug reactions.